Ziconotide

What is Ziconotide?

Ziconotide is a synthetic 25-amino-acid peptide (CKGKGAKCSRLMYDCCTGSCRSGKC, with three disulfide bridges in a conserved 'inhibitor cystine knot' fold) that is the chemical equivalent of ω-conotoxin MVIIA, a paralytic neurotoxin isolated from the venom of the Indo-Pacific fish-hunting cone snail Conus magus. It is FDA-approved (December 2004) under the brand name Prialt — originally developed by Neurex Corporation and later Elan Corporation — for the management of severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of, or refractory to, other treatments such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Ziconotide acts as a selective, reversible, high-affinity blocker of N-type voltage-gated calcium channels (Cav2.2) on the presynaptic terminals of primary afferent nociceptors in the dorsal horn of the spinal cord, silencing the release of neurotransmitters (substance P, glutamate, calcitonin gene-related peptide) that drive pain transmission. Because it is a peptide and does not cross the blood-brain barrier, ziconotide must be delivered directly into the cerebrospinal fluid via an implanted intrathecal infusion pump — there is no oral, intravenous, or subcutaneous route. The drug's defining clinical trade-off is a narrow therapeutic window: meaningful analgesia is bounded above by neuropsychiatric and cognitive adverse effects (confusion, hallucinations, abnormal gait, memory impairment, and rare suicidal ideation), and dose titration must be deliberately slow.

What Ziconotide Is Investigated For

Ziconotide occupies a narrow but genuinely valuable niche in chronic pain medicine: severe pain that has failed every prior strategy, including systemic opioids and intrathecal morphine, in a patient who can tolerate an implanted pump and lifelong specialist follow-up. The pivotal evidence base is three randomized, placebo-controlled trials. Staats and colleagues (JAMA 2004) randomized 111 patients with cancer- or AIDS-related refractory pain to intrathecal ziconotide or placebo and showed a significantly greater reduction in Visual Analog Scale of Pain Intensity scores. Rauck and colleagues (J Pain Symptom Manage 2006) randomized 220 patients with severe chronic pain to a slower-titration ziconotide protocol versus placebo. The benefit was statistically significant but modest: a 14.7% mean improvement in pain intensity versus 7.2% on placebo (p=0.036), and in the FDA label's intent-to-treat analysis of the same trial, 12% versus 5%, with “responders” (at least 30% improvement) at 16% versus 12% — a net difference of four percentage points. Tolerability, however, was markedly better than the fast-titration designs, which is why this protocol became the standard. The third randomized trial is Wallace and colleagues (Neuromodulation 2006), which randomized 255 patients with severe chronic non-malignant pain and found a 31.2% versus 6.0% mean reduction in pain intensity (p≤0.001) — but “a considerable incidence of ziconotide-associated AEs due to the rapid titration and high doses administered,” which is precisely what forced the starting and maximum doses down to the 0.1 mcg/hr and 2.4 mcg/hr figures still used today. The frequently cited Wallace 2008 and Webster 2009 datasets are open-label follow-on studies, not randomized trials. Subsequent observational and combination-therapy studies have expanded the picture to ziconotide-plus-morphine and ziconotide-plus-bupivacaine intrathecal admixtures, which are now common in tertiary pain centers. Note the divergence between practice and labeling here: PACC consensus describes these admixtures in detail, but the FDA prescribing information states that combination of ziconotide with intrathecal opiates “has not been studied in placebo-controlled clinical trials and is not recommended.” The 2017 Polyanalgesic Consensus Conference (PACC) recommendations position ziconotide as a first-line intrathecal monotherapy for nociceptive and neuropathic pain in carefully selected patients — particularly those for whom opioid escalation is contraindicated. The honest synthesis: ziconotide works, it does not cause tolerance or dependence, and for the right patient it is genuinely transformative — but the narrow therapeutic window, the requirement for an implanted pump, and the psychiatric adverse-event profile mean it remains a narrowly used specialist therapy, concentrated in high-volume intrathecal centers.

History & Discovery

Ziconotide's origin story is one of the most consequential venom-to-medicine translations in pharmacology. The genus Conus comprises roughly 800 species of marine cone snails, all of which immobilize prey using a venom apparatus (a hollow harpoon delivered from a proboscis) loaded with dozens of neurotoxic peptides. Conus magus — the 'magical cone' of the Indo-Pacific reef — is a fish-hunting species, meaning its venom must paralyze a vertebrate within seconds, which selects for highly potent and highly selective ion-channel-targeting peptides. The scientific lineage begins in the 1970s and 1980s with Baldomero 'Toto' Olivera's lab at the University of Utah. Olivera, a Filipino-American biochemist, recognized that cone snail venom was an unmined library of neuropharmacological tools and began systematically isolating and characterizing the peptides he termed 'conotoxins.' His group identified families of conotoxins targeting nicotinic acetylcholine receptors (α-conotoxins), voltage-gated sodium channels (μ-conotoxins), and voltage-gated calcium channels (ω-conotoxins), among others. The 1987 Biochemistry paper by Olivera, Cruz, McIntosh, and colleagues characterized ω-conotoxin MVIIA — a 25-amino-acid peptide from C. magus — as a selective high-affinity blocker of mammalian N-type voltage-gated calcium channels and the first pharmacological tool capable of cleanly distinguishing N-type from other calcium channel subtypes. This was the molecular event that made ziconotide possible. In the late 1980s, George Miljanich and colleagues at Neurex Corporation — a small Menlo Park biotechnology startup — licensed MVIIA, renamed it SNX-111, and began chemical synthesis (the marketed drug has never required live snails; it is produced by solid-phase peptide synthesis). Neurex pursued two parallel programs: stroke neuroprotection (the rationale being that N-type calcium channel block might prevent calcium-mediated excitotoxic neuronal death) and chronic pain. The neuroprotection program, which advanced into Phase 2/3 trials in the 1990s, ultimately failed to demonstrate clinical benefit and was discontinued. The chronic pain program, however, advanced. Early intrathecal studies in animals demonstrated potent analgesic effect without the motor side effects of intrathecal local anesthetics, and human Phase 2 studies in the mid-1990s confirmed analgesic activity in refractory chronic pain. Neurex was acquired by Elan Corporation in 1998. Elan completed Phase 3 development, including the Staats JAMA 2004 trial in cancer/AIDS pain, the Rauck J Pain Symptom Manage 2006 slow-titration trial, and the Wallace open-label long-term safety program. The FDA approved Prialt (ziconotide) on December 28, 2004 for the management of severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of, or refractory to, other treatments such as systemic analgesics, adjunctive therapies, or intrathecal morphine. The European Medicines Agency followed in 2005. Elan subsequently divested non-core assets, and Prialt's marketing rights have passed through several owners (TerSera Therapeutics now markets it in the US). Clinical adoption has been steady but narrow. Ziconotide is used in a small minority of intrathecal pump patients; intrathecal drug delivery as a whole remains underutilised and concentrated in high-volume centers — a small population, but a meaningful one for whom no other modality has worked. The 2006 Rauck slow-titration trial reshaped clinical practice by demonstrating that the early fast-titration adverse-event profile (which initially frightened many clinicians away from the drug) could be substantially mitigated by starting low and going slow. The 2017 Polyanalgesic Consensus Conference (PACC) recommendations formalized ziconotide's role as a first-line intrathecal monotherapy for selected patients and codified combination-therapy admixtures with morphine, bupivacaine, and clonidine. Twenty years after FDA approval, ziconotide remains the only marine-derived analgesic on the US market and the canonical proof that animal venoms — sculpted by millions of years of evolutionary pressure for selective receptor targeting — can yield FDA-approved precision pharmaceuticals.

How It Works

Pain signals from the body — a stubbed toe, a torn ligament, a tumor pressing on nerves — travel up nerve fibers and have to be passed across a synapse in the spinal cord before they can reach the brain. To pass the signal, the nerve ending releases neurotransmitters, and to release those neurotransmitters it has to open a specific kind of calcium channel called the N-type calcium channel. Ziconotide is a peptide that physically plugs that calcium channel. With the channel blocked, no calcium enters the nerve ending, no neurotransmitter is released, and the pain signal stops in the spinal cord before it ever reaches conscious awareness. Because the drug works at this very specific spinal-cord checkpoint and not at the brain's pleasure centers or breathing centers, it does not produce euphoria, addiction, or respiratory depression — but it does affect other neurons that use N-type channels in the brain, which is why higher doses produce confusion and other neuropsychiatric effects.

Ziconotide is a synthetic version of ω-conotoxin MVIIA, a 25-amino-acid disulfide-rich peptide from Conus magus venom that adopts the conserved 'inhibitor cystine knot' (ICK or knottin) fold characterized by three disulfide bridges in a knotted configuration that confers extreme conformational rigidity and proteolytic stability. The peptide binds with picomolar to low-nanomolar affinity to a specific extracellular site on the α1B subunit (Cav2.2) of N-type voltage-gated calcium channels, occluding the pore-region permeation pathway. This block is selective: ziconotide is highly selective for N-type over L-type, P/Q-type, R-type, and T-type calcium channels at therapeutic concentrations, a property that distinguishes it from non-selective calcium channel blockers and is the structural basis for its targeted analgesic effect. N-type calcium channels are concentrated on the presynaptic terminals of primary afferent nociceptors — the small-diameter A-delta and C fibers that carry pain information from the periphery into the dorsal horn of the spinal cord. When these afferents fire, depolarization opens the N-type channels, calcium floods in, and synaptic vesicles release excitatory neurotransmitters (substance P, glutamate, calcitonin gene-related peptide) onto second-order spinothalamic projection neurons, propagating the pain signal toward the brain. Ziconotide block of presynaptic N-type channels silences this calcium-dependent neurotransmitter release, preventing the spinal relay of nociceptive input. The block does not affect axonal conduction itself, action potentials in the afferent, or the transduction of noxious stimuli at peripheral receptors — it is purely a synaptic-relay-level intervention. The pharmacology has several important consequences. First, because the target is presynaptic and synapse-level, ziconotide does not cause numbness, motor weakness, or autonomic dysfunction in the way that local anesthetics or sodium channel blockers do — sensation and motor control are largely preserved. Second, because N-type channels are also present in central nervous system synapses outside the spinal cord pain pathway (cerebellum, hippocampus, sympathetic ganglia, autonomic ganglia), spillover of intrathecally administered drug into supraspinal CSF compartments produces dose-dependent off-target effects: cerebellar dysfunction (ataxia, nystagmus, abnormal gait), hippocampal/cortical dysfunction (memory impairment, confusion, hallucinations), and orthostatic hypotension. This anatomic distribution is the structural basis of the narrow therapeutic window. Third, the channel-level block is poorly reversible — recent electrophysiology characterises ω-conotoxin MVIIA as an effectively irreversible Cav2.2 blocker, with no current recovery after washout, in contrast to genuinely reversible experimental blockers. What makes clinical titration possible is therefore not fast unbinding at the channel but clearance from the compartment: ziconotide's terminal CSF half-life is about 4.6 hours, so within 24 hours of stopping the infusion CSF concentration falls below 5% of peak, and cognitive effects are generally reversible within two weeks (median time to reversal 3 to 15 days). Fourth, the peptide does not cross the blood-brain barrier and is not orally bioavailable, mandating intrathecal administration via implanted pump. Mechanistically, ziconotide is the prototype of a small but expanding class of N-type-selective analgesics. Subsequent efforts to develop orally bioavailable small-molecule N-type blockers (z160, NMED-160, others) have largely failed in clinical development because of off-target effects on cardiac and autonomic N-type channels — a problem that intrathecal delivery of ziconotide largely sidesteps by restricting drug exposure to the spinal cord and adjacent CNS compartments. Ziconotide also remains a key pharmacological probe for distinguishing N-type from other calcium channel subtypes in basic neuroscience, the role for which Olivera's group originally characterized it in 1987.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Ziconotide:

• 01Optimal patient-selection criteria — predicting which patients will respond to ziconotide and tolerate it well remains largely empirical, and biomarker- or psychometric-screening tools that could improve trial response rates are an active area of investigation.
• 02Position relative to intrathecal opioids in the treatment algorithm — current PACC guidance treats ziconotide as a first-line intrathecal monotherapy for nociceptive and neuropathic pain, but head-to-head randomized comparisons with intrathecal morphine and contemporary intrathecal opioid regimens are limited.
• 03Pediatric chronic pain — ziconotide is FDA-approved for adults only; controlled pediatric data are scarce, and the few published case series suggest both efficacy and a heightened tolerability concern in younger patients.
• 04Long-term (>5 year) safety in continuously infused patients — the registry and case-series literature suggests sustained analgesia without tolerance, but systematic prospective long-term safety follow-up beyond the original open-label extension cohorts is limited.
• 05Mechanism and clinical significance of long-term elevated serum creatine kinase observed in many ziconotide patients — whether this reflects a benign laboratory finding, subclinical myopathy, or something else has not been definitively resolved.
• 06Optimal intrathecal admixture combinations — ziconotide-plus-morphine, ziconotide-plus-bupivacaine, ziconotide-plus-clonidine, and triple-admixture regimens are widely used in tertiary practice based on observational data, but randomized comparative effectiveness data for most admixtures are lacking.
• 07Why the channel-level block appears effectively irreversible — ω-conotoxin MVIIA allows no current recovery after washout in electrophysiology — while clinical effects reverse over hours to days once infusion stops, and whether a genuinely reversible Cav2.2 blocker would have a wider therapeutic window.
• 08Whether the very small responder margin in the slow-titration pivotal trial (16% versus 12%) reflects an underpowered endpoint, a ceiling imposed by the 19.2 mcg/day maximum dose, or genuinely narrow efficacy — a question never formally resolved, and one that matters for how aggressively the drug should be positioned.
• 09Whether the meningitis signal is attributable to ziconotide handling specifically or to external-device intrathecal therapy generally, given that 38 of the 41 affected patients were managed with external microinfusion devices and catheters.
• 10Whether next-generation N-type calcium channel modulators (small-molecule allosteric modulators, biased blockers, peripherally restricted analogs) can achieve ziconotide's analgesic profile with a wider therapeutic window remains an active medicinal-chemistry question — multiple small-molecule attempts have failed in clinical development to date.

Forms & Administration

Ziconotide is supplied as a sterile aqueous solution (100 mcg/mL or 25 mcg/mL) for intrathecal infusion only — there is no oral, intravenous, intramuscular, or subcutaneous route, and any non-intrathecal administration is dangerous and pharmacologically pointless (the drug does not cross the blood-brain barrier and would not reach its spinal cord target). Administration requires an implanted, programmable intrathecal infusion pump — the FDA label specifies the Medtronic SynchroMed II and SynchroMed III Infusion System — connected to a catheter terminating in the lumbar or thoracic intrathecal space. Pump implantation is a sterile surgical procedure performed by trained pain physicians or neurosurgeons under general or deep sedation; the drug reservoir is refilled percutaneously in clinic at intervals of weeks to months depending on infusion rate and concentration. Per the FDA label, therapy is initiated at no more than 2.4 mcg/day (0.1 mcg/hr) and titrated upward by up to 2.4 mcg/day (0.1 mcg/hr) at intervals of no more than two to three times per week, with a minimum titration interval of 24 hours, to a recommended maximum of 19.2 mcg/day (0.8 mcg/hr) by about Day 21. Real-world effective doses sit well below that ceiling: in the slow-titration pivotal trial the mean dose at 21 days was 6.9 mcg/day, while across the entire clinical program — 662 patient-years of exposure — the average final dose was 17.6 mcg/day. Note that doses are conventionally written in mcg per day but programmed in mcg per hour, and confusing the two units is a recognised source of dosing error. There is no acute or as-needed dosing, no oral or transdermal alternative, and no self-administration outside a supervised intrathecal program. The label does contemplate external microinfusion devices as well as implanted pumps, but external catheters carry a far higher infection risk (see safety notes), so implanted systems dominate long-term use. The entire treatment is supervised by a multidisciplinary intrathecal pain team. Anyone offering ziconotide outside this controlled hospital/specialty-clinic context is misrepresenting the drug or the molecule.

Common Questions

Who Ziconotide Is NOT For

Drug & Supplement Interactions

Ziconotide is a peptide cleared by intrathecal CSF turnover and peripheral peptidase degradation; it does not undergo hepatic CYP450 metabolism or hepatic glucuronidation, and pharmacokinetic drug-drug interactions at the metabolism level are not expected. The FDA prescribing information does not require dose adjustment for concomitant CYP inhibitors, inducers, or hepatic-impairment populations. The clinically meaningful interactions are pharmacodynamic and largely involve additive central nervous system effects. CNS depressants (opioids, benzodiazepines, barbiturates, alcohol, sedating antihistamines, gabapentinoids, sedative antidepressants) potentiate ziconotide's cognitive impairment, sedation, and gait/balance effects. In practice, many ziconotide patients are concurrently on systemic opioids or benzodiazepines for breakthrough pain or anxiety, and clinicians must adjust accordingly. Intrathecal admixtures: ziconotide is commonly co-infused with morphine, hydromorphone, bupivacaine, clonidine, or baclofen in tertiary pain practice. The FDA label does not endorse these combinations — it states plainly that combination with intrathecal opiates is not recommended, having never been tested in a placebo-controlled trial — and compatibility and stability data are admixture-specific and largely outside the label, so institutional pharmacy protocols and the PACC 2017 admixture guidance should always be consulted. Combination therapy with intrathecal morphine in particular has both an efficacy rationale (complementary mechanisms) and a tolerability rationale (lower doses of each agent reduce the dose-dependent adverse-effect burden of either alone). Drugs with intrinsic neuropsychiatric or cognitive risk (anticholinergics, certain antiepileptics, dopaminergics in patients with Parkinson's disease) should be reviewed at every ziconotide visit because additive psychiatric effects can confound the dose-finding process and trigger unnecessary ziconotide dose reductions. As always, the operative reference for specific dose-adjustment and interaction guidance is the institutional protocol and the current FDA prescribing information, not this summary.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions